8ZD.F ABBISKO CAYMAN DL-00001

Healthcare Biotechnology Frankfurt Exchange
0.7600 EUR
Close of Nov 11, 2026
0.6750 1.69
Market cap
EUR 544M
P/E
-
P/B
1.83x
ROE
2.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 8ZD.F undervalued?

Graham number

The Graham number of ABBISKO CAYMAN DL-00001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ABBISKO CAYMAN DL-00001 fundamental analysis

No fundamental analysis for ABBISKO CAYMAN DL-00001 yet.

ABBISKO CAYMAN DL-00001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ABBISKO CAYMAN DL-00001

Abbisko Medicine Co., Ltd., together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR…

Full company profile